Connect with us

4 BioTech Small Cap Stocks With the Biggest Punch to Watch

Hot Biotech Penny Stocks In April 2021

Published

on

This article was originally published by PennyStocks.

Top Biotech Penny Stocks To Watch

If you are looking to invest in penny stocks, there has never been a better time than now. By definition, the term “penny stock” refers to stocks that trade under $5. Thanks to this, the low cost provides an interesting entry opportunity for investors to capitalize upon. Also, the pandemic has helped shine a light on a variety of biotech penny stocks, specifically.

When it first began in March, investors were laser-focused on biotech companies producing either Covid vaccines or treatments. Now, the market seems to have fundamentally changed, shifting the focus toward a larger range of biotech stocks. Because of this, interest in all types of companies continues to grow.

What types of biotech companies should you look out for? Well, the best way to start is to take a deep dive into a company with solid prospects. Investors should look at what stage a company’s trials are in, and if any compounds are in the commercialization stage. Also, is it producing any treatments related to Covid, such as vaccines or preventative medicines? Does the company have strong financial backing, or does this just seem to be a speculative gain?

[Learn More] Penny Stocks, How To Trade Them & Make Money In 2021

Biotech Penny Stocks To Buy?

Taking all of this into consideration, it’s important to research before deciding to buy penny stocks. While the risk can be high, the reward can be equally as enticing. Here’s a short list of penny stocks to watch as biotech heats up. I’ll leave it up to you to decide if they’re top biotech stocks to buy or if you should avoid them entirely.

Penny Stocks to Buy [or avoid]: Zomedica Corp.

While Zomedica Corp. hasn’t had the best month, it seems like things may be about to change. It develops and commercializes products for companion pets. There are currently a few things that are affecting shares of ZOM stock. The first of which is Zomedica’s year-end 2020 financial results.

The company recorded a net loss and no revenue. Despite this, it did see improvement in parts of its balance sheet. The CEO of Zomedica, Robert Cohen, stated, “While we are thankful for our substantially improved balance sheet, we continue to be good stewards of our funds by remaining efficient in our operations as we prepare for the upcoming commercial release of TRUFORMA®.”

On March 16th, Zomedica announced its first commercial sale of Truforma. Cohen added, “This is a momentous day for Zomedica, our shareholders, the veterinarians we serve, and the companion animals in their care.”

With the commercial launch of TRUFORMA and new capital being raised, now is the time for Zomedica to scale things out. Selling a few initial units is great, but with the door open to full industry sales, traders are looking for growth. Heading into the second quarter, this will be something to keep a close eye on. Needless to say, ZOM stock has experienced a big year so far. Shares have climbed from around $0.25 in January to over $1.40 this week.

Penny_Stocks_to_Watch_Zomedica Corp. (ZOM Stock Chart)

Auris Medical Holding Ltd.

Another penny stock that climbed substantially on Thursday is Auris Medical Holdings Ltd. The clinical-stage biotech company creates therapeutics for neurology, rhinology, allergy, and CNS disorders. Auris provided a business update around a week ago and reported its second half and full-year 2020 financial results. Its business update included the announcement of progression with its clinical evaluation of AM-301 taken intra-nasally. The treatment has already been shown to reduce SARS-CoV-2 virus titers in animals. The company expects to launch this quarter.

The Chairman and CEO of Auris, Thomas Meyer, said, “With a highly dedicated team, we managed to develop in less than six months a drug-free nasal spray that reduced the SARS-CoV-2 viral titer in a model representative of the human nasal mucosa by more than 99%.”

[Read More] Trading Penny Stocks? 5 You Can Buy Under $1 On Robinhood Right Now

This product could be huge if it continues to be this effective and makes it to market.  Auris plans to announce a business update on its AM-301 program next Tuesday on April 13th. While this announcement’s details are not clear right now, only time will tell what is on the horizon for EARS stock. Ahead of this update, shares climbed over 18% on April 8th.

Oncolytics Biotech Inc.

Now let’s talk about Oncolytics Biotech, a development stage company focused on discovering and developing pharmaceutical products to treat cancer. The world is always looking for new cancer treatments and hopefully someday a cure. This makes the role of these biotech companies huge, attracting investors along the way. This week Oncolytics announced that it would participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15th, 2021.

This announcement seems to have piqued investor interest. ONCY stock is up over 5% following the announcement. Just 3 days earlier, Oncolytics announced that it will host a key opinion leader webinar to discuss its AWARE-1 data, the immunotherapeutic effects of Pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. This webinar will take place on April 12th, 2021. So next week could be a defining week for Oncolytics if a lot of good progress is announced.

Genprex Inc.

The last biotech penny stock on this list, Genprex, is a clinical-stage gene therapy-focused company working on treating cancer patients and those with diabetes. As mentioned before, companies focused on cancer treatment often have solid market performance. Diabetes is also a disease that affects millions, making the market for treatments huge. 

On March 30th, Genprex announced that preclinical data for TUSC2 immunogen therapy in non-small cell lung cancer would be presented soon. This data will be featured in two presentations at the 2021 American Association for Cancer Research Annual Meeting. This meeting takes place on April 10th.

[Read More] 3 Penny Stocks On Robinhood To Buy Under $4 Right Now

President and CEO Rodney Varner stated, “We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers.”

The hype is there for this news release, but could this be a case where investors buy the rumor and sell the news? Only time will tell, and it likely could depend on what is in these results.

Biotech Penny Stocks & Volatility

It’s important to understand how volatile biotech stocks can be, in general. I’m not only talking about small-caps but the sector as a whole. The fact that these companies are dealing with life-changing treatments means there’s little room for error. In this case, things like trial data are essential.

When companies report a miss of an endpoint or a notice from the FDA not to proceed with phase trials, it can raise red flags until the company gives clarity. On the other hand, when companies announce breakthrough developments like big progress in phase trials, it can be a green light for traders and investors to rally behind a company. In either case, it can make for a very wild situation in the stock market.

The post Best Penny Stocks To Buy In April 2021? 4 Biotechs For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Government

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former…

Published

on

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former Project Veritas & O’Keefe Media Group operative and Pfizer formulation analyst scientist Justin Leslie revealed previously unpublished recordings showing Pfizer’s top vaccine researchers discussing major concerns surrounding COVID-19 vaccines. Leslie delivered these recordings to Veritas in late 2021, but they were never published:

Featured in Leslie’s footage is Kanwal Gill, a principal scientist at Pfizer. Gill was weary of MRNA technology given its long research history yet lack of approved commercial products. She called the vaccines “sneaky,” suggesting latent side effects could emerge in time.

Gill goes on to illustrate how the vaccine formulation process was dramatically rushed under the FDA’s Emergency Use Authorization and adds that profit incentives likely played a role:

"It’s going to affect my heart, and I’m going to die. And nobody’s talking about that."

Leslie recorded another colleague, Pfizer’s pharmaceutical formulation scientist Ramin Darvari, who raised the since-validated concern that repeat booster intake could damage the cardiovascular system:

None of these claims will be shocking to hear in 2024, but it is telling that high-level Pfizer researchers were discussing these topics in private while the company assured the public of “no serious safety concerns” upon the jab’s release:

Vaccine for Children is a Different Formulation

Leslie sent me a little-known FDA-Pfizer conference — a 7-hour Zoom meeting published in tandem with the approval of the vaccine for 5 – 11 year-olds — during which Pfizer’s vice presidents of vaccine research and development, Nicholas Warne and William Gruber, discussed a last-minute change to the vaccine’s “buffer” — from “PBS” to “Tris” — to improve its shelf life. For about 30 seconds of these 7 hours, Gruber acknowledged that the new formula was NOT the one used in clinical trials (emphasis mine):


“The studies were done using the same volume… but contained the PBS buffer. We obviously had extensive consultations with the FDA and it was determined that the clinical studies were not required because, again, the LNP and the MRNA are the same and the behavior — in terms of reactogenicity and efficacy — are expected to be the same.

According to Leslie, the tweaked “buffer” dramatically changed the temperature needed for storage: “Before they changed this last step of the formulation, the formula was to be kept at -80 degrees Celsius. After they changed the last step, we kept them at 2 to 8 degrees celsius,” Leslie told me.

The claims are backed up in the referenced video presentation:

I’m no vaccinologist but an 80-degree temperature delta — and a 5x shelf-life in a warmer climate — seems like a significant change that might warrant clinical trials before commercial release.

Despite this information technically being public, there has been virtually no media scrutiny or even coverage — and in fact, most were told the vaccine for children was the same formula but just a smaller dose — which is perhaps due to a combination of the information being buried within a 7-hour jargon-filled presentation and our media being totally dysfunctional.

Bohemian Grove?

Leslie’s 2-hour long documentary on his experience at both Pfizer and O’Keefe’s companies concludes on an interesting note: James O’Keefe attended an outing at the Bohemian Grove.

Leslie offers this photo of James’ Bohemian Grove “GATE” slip as evidence, left on his work desk atop a copy of his book, “American Muckraker”:

My thoughts on the Bohemian Grove: my good friend’s dad was its general manager for several decades. From what I have gathered through that connection, the Bohemian Grove is not some version of the Illuminati, at least not in the institutional sense.

Do powerful elites hangout there? Absolutely. Do they discuss their plans for the world while hanging out there? I’m sure it has happened. Do they have a weird ritual with a giant owl? Yep, Alex Jones showed that to the world.

My perspective is based on conversations with my friend and my belief that his father is not lying to him. I could be wrong and am open to evidence — like if boxer Ryan Garcia decides to produce evidence regarding his rape claims — and I do find it a bit strange the club would invite O’Keefe who is notorious for covertly filming, but Occam’s razor would lead me to believe the club is — as it was under my friend’s dad — run by boomer conservatives the extent of whose politics include disliking wokeness, immigration, and Biden (common subjects of O’Keefe’s work).

Therefore, I don’t find O’Keefe’s visit to the club indicative that he is some sort of Operation Mockingbird asset as Leslie tries to depict (however Mockingbird is a 100% legitimate conspiracy). I have also met James several times and even came close to joining OMG. While I disagreed with James on the significance of many of his stories — finding some to be overhyped and showy — I never doubted his conviction in them.

As for why Leslie’s story was squashed… all my sources told me it was to avoid jail time for Veritas executives.

Feel free to watch Leslie’s full documentary here and decide for yourself.

Fun fact — Justin Leslie was also the operative behind this mega-viral Project Veritas story where Pfizer’s director of R&D claimed the company was privately mutating COVID-19 behind closed doors:

Tyler Durden Tue, 03/12/2024 - 13:40

Read More

Continue Reading

International

Association of prenatal vitamins and metals with epigenetic aging at birth and in childhood

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging…

Published

on

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

Credit: 2024 Bozack et al.

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

BUFFALO, NY- March 12, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 4, entitled, “Associations of prenatal one-carbon metabolism nutrients and metals with epigenetic aging biomarkers at birth and in childhood in a US cohort.”

Epigenetic gestational age acceleration (EGAA) at birth and epigenetic age acceleration (EAA) in childhood may be biomarkers of the intrauterine environment. In this new study, researchers Anne K. Bozack, Sheryl L. Rifas-Shiman, Andrea A. Baccarelli, Robert O. Wright, Diane R. Gold, Emily Oken, Marie-France Hivert, and Andres Cardenas from Stanford University School of Medicine, Harvard Medical School, Harvard T.H. Chan School of Public Health, Columbia University, and Icahn School of Medicine at Mount Sinai investigated the extent to which first-trimester folate, B12, 5 essential and 7 non-essential metals in maternal circulation are associated with EGAA and EAA in early life. 

“[…] we hypothesized that OCM [one-carbon metabolism] nutrients and essential metals would be positively associated with EGAA and non-essential metals would be negatively associated with EGAA. We also investigated nonlinear associations and associations with mixtures of micronutrients and metals.”

Bohlin EGAA and Horvath pan-tissue and skin and blood EAA were calculated using DNA methylation measured in cord blood (N=351) and mid-childhood blood (N=326; median age = 7.7 years) in the Project Viva pre-birth cohort. A one standard deviation increase in individual essential metals (copper, manganese, and zinc) was associated with 0.94-1.2 weeks lower Horvath EAA at birth, and patterns of exposures identified by exploratory factor analysis suggested that a common source of essential metals was associated with Horvath EAA. The researchers also observed evidence of nonlinear associations of zinc with Bohlin EGAA, magnesium and lead with Horvath EAA, and cesium with skin and blood EAA at birth. Overall, associations at birth did not persist in mid-childhood; however, arsenic was associated with greater EAA at birth and in childhood. 

“Prenatal metals, including essential metals and arsenic, are associated with epigenetic aging in early life, which might be associated with future health.”

 

Read the full paper: DOI: https://doi.org/10.18632/aging.205602 

Corresponding Author: Andres Cardenas

Corresponding Email: andres.cardenas@stanford.edu 

Keywords: epigenetic age acceleration, metals, folate, B12, prenatal exposures

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Trending